IGN523

News alerts, weekly reports and conference planners

Company:

Igenica Biotherapeutics

Drug class:

CD98 inhibitor

‹

›

5years

Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML. (PubMed, Hematol Oncol)

Herein, we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral blood stem cell (PBSC) support, in order to limit toxicity, according to Northern Italy Leukemia Group (NILG) AML-01/00 study (EUDRACT number 00400673). In conclusion, consolidation including repeated courses of HDAC and idarubicin, with limited PBSC support, proved feasible and very effective in non-high risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis.

5 years ago

Clinical • Journal

FLT3 (Fms-related tyrosine kinase 3) • CD34 (CD34 molecule)

FLT3-ITD mutation

cytarabine • idarubicin hydrochloride • IGN523

over5years

Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment. (PubMed, Leuk Lymphoma)

PDGFRB expression was upregulated in MMSCs from patients in relapse versus those in remission. The AML 01.10 protocol downregulates the expression of genes related to proliferation, differentiation and niche formation.

over 5 years ago

Clinical • Journal

FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IL6 (Interleukin 6) • ICAM1 (Intercellular adhesion molecule 1) • FGF2 (Fibroblast Growth Factor 2) • SOX9 (SRY-Box Transcription Factor 9) • IL1B (Interleukin 1, beta)

IGN523